{"id":"oxaliplatin-intra-arteriel","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL414804","moleculeType":"Small molecule","molecularWeight":"395.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxaliplatin is a third-generation platinum compound that binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription. When administered intra-arterially, it achieves high local drug concentrations in hepatic tumors while reducing systemic exposure. This regional delivery approach is designed to improve efficacy against colorectal cancer liver metastases while potentially reducing systemic toxicity.","oneSentence":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, delivered directly into the hepatic artery to maximize local concentration in liver tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:07.327Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer with hepatic metastases (intra-arterial administration)"}]},"trialDetails":[{"nctId":"NCT02885753","phase":"PHASE3","title":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-12","conditions":"Colorectal Neoplasms","enrollment":348}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oxaliplatin IA"],"phase":"phase_3","status":"active","brandName":"Oxaliplatin intra-arteriel","genericName":"Oxaliplatin intra-arteriel","companyName":"Federation Francophone de Cancerologie Digestive","companyId":"federation-francophone-de-cancerologie-digestive","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, delivered directly into the hepatic artery to maximize local concentration in liver tumors. Used for Colorectal cancer with hepatic metastases (intra-arterial administration).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}